Chemotherapy-Induced Febrile Neutropenia
Conditions
Keywords
Febrile Neutropenia, Breast Cancer, Chemotherapy
Brief summary
The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
Detailed description
Patients with stage invasive breast cancer who were scheduled to receive at least 2 cycles of adjuvant or neoadjuvant chemotherapy with TAC/TC/TCbH regimen were eligible for this multicenter, open-label, randomized trial. Patients were randomized (2:1) to receive QL0605 24 hours (24h group) or 48 hours (48h group) after the end of each cycle of chemotherapy. The primary endpoint was the incidence rate of FN for cycle 1. The secondary endpoints included the incidence rates of grade 3/4 neutropenia, chemotherapy dose reduction and chemotherapy delay due to neutropenia, antibiotic administration, the pain (bone, muscle, or joint), ect.
Interventions
DRUGQL0605(PEG-rhG-CSF)
Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged≥18 years； * The expected survival period is more than 3 months; * ECOG≤ 2; * Invasive breast cancer diagnosed by histopathology; * Plan to receive TAC, TC or TCbH chemotherapy; * Subjects with good hematology, liver, lung and kidney function ; * Signed informed consent.
Exclusion criteria
* Known hypersensitivity to rhG-CSF or PEG-rhG-CSF; * Female patients during pregnancy or lactation; * The previous malignant tumors were not cured; * Received chemotherapy or radiotherapy within 4 weeks before screening; * Received PEG-rhG-CSF within 6 weeks before screening; * Suffering from uncontrollable infectious diseases within 2 weeks before screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of febrile neutropenia for chemotherapy cycle 1. | 21 days (Cycle 1 of chemotherapy treatment) | Febrile neutropenia is defined as single temperature: ≥38.3 °C orally（axillary 38.1°C） or ≥38.0 °C（axillary 37.8°C） over 2h; and neutropenia: \<500 neutrophils/mcL. |
Countries
China
Contacts
Primary ContactMengli Zhu, Master
Backup ContactWangwang Zhi, Master
Outcome results
None listed